| Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ... Annals of oncology 28, iv1-iv21, 2017 | 1717 | 2017 |
| Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, ... The Lancet 393 (10185), 2051-2058, 2019 | 1572 | 2019 |
| Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials Chang Lancet Oncology 16, 630-7, 2015 | 1553 | 2015 |
| Prophylactic cranial irradiation in extensive small-cell lung cancer B Slotman, C Faivre-Finn, G Kramer, E Rankin, M Snee, M Hatton, ... New England Journal of Medicine 357 (7), 664-672, 2007 | 1316 | 2007 |
| Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ... Annals of Oncology 27, v1-v27, 2016 | 985 | 2016 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, ... Journal of Clinical Oncology 38 (25), 2830, 2020 | 838 | 2020 |
| Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery … T Treasure, L Lang-Lazdunski, D Waller, JM Bliss, C Tan, J Entwisle, ... The lancet oncology 12 (8), 763-772, 2011 | 769 | 2011 |
| Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis DA Palma, S Senan, K Tsujino, RB Barriger, R Rengan, M Moreno, ... International Journal of Radiation Oncology* Biology* Physics 85 (2), 444-450, 2013 | 695 | 2013 |
| Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up J Vansteenkiste, D De Ruysscher, WEE Eberhardt, E Lim, S Senan, ... Annals of oncology 24, vi89-vi98, 2013 | 638 | 2013 |
| Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study WFAR Verbakel, JP Cuijpers, D Hoffmans, M Bieker, BJ Slotman, ... International Journal of Radiation Oncology* Biology* Physics 74 (1), 252-259, 2009 | 619 | 2009 |
| Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non–small-cell lung cancer FJ Lagerwaard, CJA Haasbeek, EF Smit, BJ Slotman, S Senan International Journal of Radiation Oncology* Biology* Physics 70 (3), 685-692, 2008 | 613 | 2008 |
| Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, ... Journal of Clinical Oncology 40 (12), 1301, 2022 | 587 | 2022 |
| Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial BJ Slotman, H van Tinteren, JO Praag, JL Knegjens, SY El Sharouni, ... The Lancet 385 (9962), 36-42, 2015 | 586 | 2015 |
| 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ... Annals of Oncology 25 (8), 1462-1474, 2014 | 535 | 2014 |
| Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non–small-cell lung cancer: a population-based time-trend analysis D Palma, O Visser, FJ Lagerwaard, J Belderbos, BJ Slotman, S Senan Journal of clinical oncology 28 (35), 5153-5159, 2010 | 531 | 2010 |
| Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis S Senthi, FJ Lagerwaard, CJA Haasbeek, BJ Slotman, S Senan The lancet oncology 13 (8), 802-809, 2012 | 509 | 2012 |
| European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer D De Ruysscher, C Faivre-Finn, U Nestle, CW Hurkmans, C Le Péchoux, ... Journal of clinical oncology 28 (36), 5301-5310, 2010 | 490* | 2010 |
| PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced … S Senan, A Brade, L Wang, J Vansteenkiste, S Dakhil, B Biesma, ... Journal of clinical oncology 34 (9), 953-962, 2016 | 480 | 2016 |
| An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer AB Ashworth, S Senan, DA Palma, M Riquet, YC Ahn, U Ricardi, ... Clinical lung cancer 15 (5), 346-355, 2014 | 442 | 2014 |
| Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and … C Le Péchoux, A Dunant, S Senan, A Wolfson, E Quoix, C Faivre-Finn, ... The lancet oncology 10 (5), 467-474, 2009 | 430 | 2009 |
